Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation - Schedule of Summarizes Information About Stock Options (Details)

v3.21.1
Stock-Based Compensation - Schedule of Summarizes Information About Stock Options (Details)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
shares
2014 Long Term Incentive Equity Plan [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Stock Options Outstanding, Beginning Balance | shares 6,798,529
Number of Stock Options, Granted | shares 350,000 [1]
Number of Stock Option, Exercised | shares (80,000)
Number of Stock Option, Forfeited | shares (25,833)
Number of Stock Options Outstanding, Ending Balance | shares 7,042,696
Number of Stock Options Vested and exercisable stock options | shares 5,216,860
Weighted Average Exercise Price, Beginning Balance | $ / shares $ 2.55
Weighted Average Exercise Price, Granted | $ / shares 2.96
Weighted Average Exercise Price, Exercised | $ / shares 1.00
Weighted Average Exercise Price, Forfeited | $ / shares 2.44
Weighted Average Exercise Price, Ending Balance | $ / shares 2.59
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares $ 2.80
Remaining Contractual Term (Years) stock options, Ending Balance 7 years 2 months 12 days
Remaining Contractual Term (Years), Vested and exercisable stock options 6 years 7 months 6 days
Intrinsic Value of Outstanding Stock Option, Ending Balance | $ $ 14,425 [2]
Intrinsic Value of Vested and Exercisable Stock Option, Ending Balance | $ $ 9,938 [2]
2018 Long Term Incentive Equity Plan [Member]  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Number of Stock Options Outstanding, Beginning Balance | shares 991,667
Number of Stock Options, Granted | shares [1]
Number of Stock Option, Exercised | shares
Number of Stock Option, Forfeited | shares
Number of Stock Options Outstanding, Ending Balance | shares 991,667
Number of Stock Options Vested and exercisable stock options | shares 838,749
Weighted Average Exercise Price, Beginning Balance | $ / shares $ 0.86
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Forfeited | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares 0.86
Weighted Average Exercise Price, Vested and exercisable stock options | $ / shares $ 0.83
Remaining Contractual Term (Years) stock options, Beginning 8 years
Remaining Contractual Term (Years) stock options, Ending Balance 7 years 8 months 12 days
Remaining Contractual Term (Years), Vested and exercisable stock options 7 years 8 months 12 days
[1] Stock options granted under the PAVmed Inc. 2014 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.
[2] The intrinsic value is computed as the difference between the quoted price of the PAVmed Inc. common stock on each of March 31, 2021 and December 31, 2020 and the exercise price of the underlying PAVmed Inc. stock options, to the extent such quoted price is greater than the exercise price.